EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

RNA Therapeutics: Delivery Problems and Solutions—A Review

Natalia Pozdniakova iD, Evgenii Generalov iD, Alexei Shevelev, Olga Tarasova iD

Pharmaceutics · 07.10.2025 · 17 (10) · 1305

DOI: 10.3390/pharmaceutics17101305 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 07.10.2025. Verfasst von Natalia Pozdniakova und 3 weiteren Autor:innen. Beteiligte Einrichtung: Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, 115522 Moscow, Russia. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 226 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Program for Basic Research in the Russian Federation for a long-term period (2021-2030).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RNA-based therapeutics offer transformative potential for treating devastating diseases. However, current RNA delivery technologies face significant hurdles, including inefficient tissue targeting, insufficient selectivity, and severe side effects, leading to the termination of many clinical trials. This review critically assesses the landscape of RNA-derived medicines, examining world-renowned mRNA vaccines (Spikevax, BNT162b2/Comirnaty) and RNA-based therapeutics like Miravirsen (anti-miR-122). It details the composition and clinical trial results of numerous modified short RNA drugs (e.g., siRNAs, miRNA mimetics/inhibitors) targeting various conditions. Prospects for RNA-based medicines are analysed for diseases with substantial societal impact, such as cancer, autoimmune disorders, and infectious diseases, with a focus on evolving delivery methods, including lipid nanoparticles, viral vectors, and exosomes. RNA-mediated macrophage reprogramming emerges as a promising strategy, potentially enhancing both delivery and clinical efficacy. This review highlights that while approved RNA therapies primarily target rare diseases due to delivery limitations, novel approaches in RNA modification, targeted delivery systems, and enhanced understanding of molecular mechanisms are crucial for expanding their application to prevalent diseases and unlocking their full therapeutic potential.

Schlagwörter

Stichwörter der Autor:innen

AAV vectorsRNARNA mimeticRNA vaccineexosomeslipid nanoparticlesmacrophage reprogrammingviral vectors

Autor:innen und Institutionen

  • Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, 115522 Moscow, Russia.
  • Faculty of Physics, Lomonosov Moscow State University, 119991 Moscow, Russia.
  • Vavilov Institute of General Genetics of Russian Academy of Sciences, 119991 Moscow, Russia.
  • Institute of Biomedical Chemistry of Russian Academy of Sciences, 119121 Moscow, Russia.

ORCID-Profile: Natalia Pozdniakova, Evgenii Generalov, Olga Tarasova

Förderung

  • Program for Basic Research in the Russian Federation for a long-term period (2021-2030)

Zitieren

APA

Pozdniakova, N., Generalov, E., Shevelev, A., & Tarasova, O. (2025). RNA Therapeutics: Delivery Problems and Solutions—A Review. Pharmaceutics, 17(10), 1305. https://doi.org/10.3390/pharmaceutics17101305

Vancouver

Pozdniakova N, Generalov E, Shevelev A, Tarasova O. RNA Therapeutics: Delivery Problems and Solutions—A Review. Pharmaceutics. 2025;17(10):1305. doi:10.3390/pharmaceutics17101305

BibTeX
@article{Pozdniakova2025,
  author = {Pozdniakova, Natalia and Generalov, Evgenii and Shevelev, Alexei and Tarasova, Olga},
  title = {RNA Therapeutics: Delivery Problems and Solutions—A Review},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {10},
  pages = {1305},
  doi = {10.3390/pharmaceutics17101305}
}
Kostenlos starten →